EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC 4.0

Remarkable Response to Iruplinalkib in an Elderly Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Case Report

Jie Tian, Xingpo Li, Ying Zhang, Haibo Hu

Case Reports in Oncology · 17.03.2026 · 19 (1) · 599-605

DOI: 10.1159/000551593 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Case Reports in Oncology, online erschienen am 17.03.2026. Verfasst von Jie Tian und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Huantai County Hospital of Traditional Chinese Medicine, Zibo, China. Die Arbeit nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) typically affects younger patients. Management in elderly patients with significant comorbidities presents unique diagnostic and therapeutic challenges. Data regarding the efficacy and safety of iruplinalkib in elderly patients remain limited. Case Presentation: We report a 79-year-old male who presented with massive pleural effusion and multiple rib fractures. Initial diagnosis was established through pleural fluid cytology revealing adenocarcinoma. Following clinical stabilization, computed tomography-guided lung biopsy confirmed ALK-positive invasive adenocarcinoma. Treatment with iruplinalkib 180 mg once daily achieved a remarkable tumor response, with resolution of pleural effusion and significant reduction in tumor burden over 29 weeks. Treatment was well tolerated, with only mild gastrointestinal adverse events.

Conclusion

This case demonstrates that iruplinalkib exhibits excellent efficacy and tolerability in elderly patients with ALK-positive NSCLC, even in those presenting with advanced disease and poor initial performance status. Age alone should not preclude consideration of targeted therapy when actionable driver mutations are identified.

Schlagwörter

Stichwörter der Autor:innen

Anaplastic lymphoma kinase-positive lung adenocarcinomaCase reportElderly patientIruplinalkibTargeted therapy

Autor:innen und Institutionen

  • Department of Cardiology, Huantai County Hospital of Traditional Chinese Medicine, Zibo, China.

Zitieren

APA

Tian, J., Li, X., Zhang, Y., & Hu, H. (2026). Remarkable Response to Iruplinalkib in an Elderly Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Case Report. Case Reports in Oncology, 19(1), 599-605. https://doi.org/10.1159/000551593

Vancouver

Tian J, Li X, Zhang Y, Hu H. Remarkable Response to Iruplinalkib in an Elderly Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Case Report. Case Reports in Oncology. 2026;19(1):599-605. doi:10.1159/000551593

BibTeX
@article{Tian2026,
  author = {Tian, Jie and Li, Xingpo and Zhang, Ying and Hu, Haibo},
  title = {Remarkable Response to Iruplinalkib in an Elderly Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Case Report},
  journal = {Case Reports in Oncology},
  year = {2026},
  volume = {19},
  number = {1},
  pages = {599--605},
  doi = {10.1159/000551593}
}
Kostenlos starten →